| scholarly article | Q13442814 |
| P2093 | author name string | Angie Gelli | |
| Kiem Vu | |||
| Javier A Garcia | |||
| P2860 | cites work | The Cryptococcus neoformans capsule: a sword and a shield | Q24619875 |
| Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal | Q27012487 | ||
| Synergistic combinations of antifungals and anti-virulence agents to fight against Candida albicans | Q28082407 | ||
| Mechanisms and functions of Eph and ephrin signalling | Q28208291 | ||
| Cryptococcus neoformans resides in an acidic phagolysosome of human macrophages | Q28295002 | ||
| Increased permeability of blood-brain barrier is mediated by serine protease during Cryptococcus meningitis | Q28305427 | ||
| Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS | Q29617372 | ||
| Eph receptor signalling casts a wide net on cell behaviour | Q29619988 | ||
| Cryptococcal meningitis. | Q54075694 | ||
| Antifungal Combinations for Treatment of Cryptococcal Meningitis in Africa. | Q54255992 | ||
| Arylamino containing hydroxamic acids as potent urease inhibitors for the treatment of Helicobacter pylori infection | Q57091995 | ||
| Flurofamide: a potent inhibitor of bacterial urease with potential clinical utility in the treatment of infection induced urinary stones | Q70220406 | ||
| The capsule of cryptococcus neoformans passively inhibits phagocytosis of the yeast by macrophages | Q70254971 | ||
| Treatment with monoclonal antibodies against Clostridium difficile toxins | Q84070721 | ||
| Fungal infections of the central nervous system | Q86996872 | ||
| The Early Innate Immune Response to, and Phagocyte-Dependent Entry of, Cryptococcus neoformans Map to the Perivascular Space of Cortical Post-Capillary Venules in Neurocryptococcosis | Q89180669 | ||
| Cryptococcal transmigration across a model brain blood-barrier: evidence of the Trojan horse mechanism and differences between Cryptococcus neoformans var. grubii strain H99 and Cryptococcus gattii strain R265. | Q38835353 | ||
| Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance | Q39197564 | ||
| Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis | Q39379643 | ||
| 1,2-Benzisoselenazol-3(2H)-one Derivatives As a New Class of Bacterial Urease Inhibitors | Q40576160 | ||
| EphrinA1-induced cytoskeletal re-organization requires FAK and p130(cas). | Q40716314 | ||
| Microvilli-like structures are associated with the internalization of virulent capsulated Neisseria meningitidis into vascular endothelial cells. | Q40745925 | ||
| Cryptococcus neoformans promotes its transmigration into the central nervous system by inducing molecular and cellular changes in brain endothelial cells | Q41886935 | ||
| Astrocytic tight junctions control inflammatory CNS lesion pathogenesis | Q42644144 | ||
| The Human Blood-Brain Barrier Internalizes Cryptococcus neoformans via the EphA2-Tyrosine Kinase Receptor. | Q46361858 | ||
| Involvement of human CD44 during Cryptococcus neoformans infection of brain microvascular endothelial cells | Q46481054 | ||
| Development of Anti-Virulence Approaches for Candidiasis via a Novel Series of Small-Molecule Inhibitors of Candida albicans Filamentation | Q47189974 | ||
| Ephrin receptor A2 is a functional entry receptor for Epstein-Barr virus. | Q47559100 | ||
| Discovery of a Novel Dibromoquinoline Compound Exhibiting Potent Antifungal and Antivirulence Activity That Targets Metal Ion Homeostasis | Q48164716 | ||
| Cryptococcus neoformans induces alterations in the cytoskeleton of human brain microvascular endothelial cells | Q48177549 | ||
| Pathogenesis of cerebral Cryptococcus neoformans infection after fungemia | Q48500734 | ||
| An expanded family of fungalysin extracellular metallopeptidases of Coprinopsis cinerea. | Q53495009 | ||
| Malaria parasites target the hepatocyte receptor EphA2 for successful host infection | Q30047034 | ||
| Approval of Raxibacumab for the Treatment of Inhalation Anthrax Under the US Food and Drug Administration "Animal Rule". | Q30201937 | ||
| Cryptococcal meningitis: epidemiology, immunology, diagnosis and therapy | Q30240687 | ||
| Replication of Cryptococcus neoformans in macrophages is accompanied by phagosomal permeabilization and accumulation of vesicles containing polysaccharide in the cytoplasm | Q30476172 | ||
| Real-time imaging of trapping and urease-dependent transmigration of Cryptococcus neoformans in mouse brain. | Q30494253 | ||
| Invasion of the central nervous system by Cryptococcus neoformans requires a secreted fungal metalloprotease. | Q33724907 | ||
| The Metalloprotease, Mpr1, Engages AnnexinA2 to Promote the Transcytosis of Fungal Cells across the Blood-Brain Barrier | Q33857975 | ||
| Laccase of Cryptococcus neoformans is a cell wall-associated virulence factor | Q34008955 | ||
| Immune modulation mediated by cryptococcal laccase promotes pulmonary growth and brain dissemination of virulent Cryptococcus neoformans in mice. | Q34460637 | ||
| Human botulism immune globulin for the treatment of infant botulism | Q34490632 | ||
| How do extracellular pathogens cross the blood-brain barrier? | Q34522621 | ||
| Phagosome extrusion and host-cell survival after Cryptococcus neoformans phagocytosis by macrophages | Q34579227 | ||
| CPS1, a homolog of the Streptococcus pneumoniae type 3 polysaccharide synthase gene, is important for the pathobiology of Cryptococcus neoformans | Q34720974 | ||
| Evidence of a role for monocytes in dissemination and brain invasion by Cryptococcus neoformans | Q34860542 | ||
| Urease expression by Cryptococcus neoformans promotes microvascular sequestration, thereby enhancing central nervous system invasion | Q35098130 | ||
| Evaluation of a newly developed lateral flow immunoassay for the diagnosis of cryptococcosis | Q35141239 | ||
| The emerging role of urease as a general microbial virulence factor | Q35169182 | ||
| 4-methylumbelliferone treatment and hyaluronan inhibition as a therapeutic strategy in inflammation, autoimmunity, and cancer | Q35206080 | ||
| EphrinA2 receptor (EphA2) is an invasion and intracellular signaling receptor for Chlamydia trachomatis | Q35533099 | ||
| Quorum quenching quandary: resistance to antivirulence compounds | Q35758927 | ||
| Hyaluronic acid receptor CD44 deficiency is associated with decreased Cryptococcus neoformans brain infection | Q35939738 | ||
| Identification and characterization of CPS1 as a hyaluronic acid synthase contributing to the pathogenesis of Cryptococcus neoformans infection | Q35947140 | ||
| Cryptococcus neoformans phospholipase B1 activates host cell Rac1 for traversal across the blood-brain barrier | Q36236518 | ||
| Cryptococcus neoformans activates RhoGTPase proteins followed by protein kinase C, focal adhesion kinase, and ezrin to promote traversal across the blood-brain barrier | Q36332842 | ||
| Role of extracellular phospholipases and mononuclear phagocytes in dissemination of cryptococcosis in a murine model | Q37116098 | ||
| Invasion of Cryptococcus neoformans into human brain microvascular endothelial cells requires protein kinase C-alpha activation | Q37312232 | ||
| The capsule of the fungal pathogen Cryptococcus neoformans | Q37337879 | ||
| Immortalized human brain endothelial cell line HCMEC/D3 as a model of the blood-brain barrier facilitates in vitro studies of central nervous system infection by Cryptococcus neoformans | Q37410097 | ||
| Cryptococcal yeast cells invade the central nervous system via transcellular penetration of the blood-brain barrier | Q37521730 | ||
| Trojan Horse Transit Contributes to Blood-Brain Barrier Crossing of a Eukaryotic Pathogen. | Q37617655 | ||
| Targeting Candida albicans filamentation for antifungal drug development. | Q37705311 | ||
| Advanced HIV disease in Botswana following successful antiretroviral therapy rollout: Incidence of and temporal trends in cryptococcal meningitis. | Q38785746 | ||
| Obiltoxaximab: First Global Approval | Q38809942 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | meningitis | Q48143 |
| Cryptococcus neoformans | Q131924 | ||
| cryptococcal meningitis | Q18967011 | ||
| P304 | page(s) | 353 | |
| P577 | publication date | 2019-01-01 | |
| P1433 | published in | Frontiers in Microbiology | Q27723481 |
| P1476 | title | Cryptococcal Meningitis and Anti-virulence Therapeutic Strategies | |
| P478 | volume | 10 |
Search more.